IXICO PLC · LSE:IXI
IXICO — FY2019 Earnings Presentation
30 slides from IXICO's earnings presentation, Dec 4, 2019

Slide 1: Advanced analytics. Intelligent insights – 2019 Results
Advanced analytics. Intelligent insights 2019 Results Giulio Cerroni, CEO Grant Nash, CFO AIM: IXI 4th December 2019

Slide 2: Disclaimer
Disclaimer – NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. – The information contained in these slides and the presentation is strictly confidential, and is supplied on the under

Slide 3: AI Data Analytics in Neurological Diseases
AI Data Analytics in Neurological Diseases 2019 Results Giulio Cerroni, CEO AIM: IXI

Slide 4: 5 point growth strategy
5 point growth strategy Focus on Accelerate Target early Innovate: Enhance organic delivering scale penetration phase to grow AI machine- growth through and operational of clinical trials into later clinical learning data selective excellence market; diversify phases analytics partnerships into new

Slide 5: Leadership Team
Leadership Team Giulio Cerroni (Feb ‘17) Chief Executive Officer Grant Nash Alison Howie (April ‘19) (Jun ‘18) Chief Financial Officer Chief Product Officer Marcus Thornton Robin Wolz (Jun ‘18) (Mar ‘14) Chief Operating Officer SVP Science & Innovation Lammert Albers (Oct ‘19) Chief Business Officer

Slide 6: Investment case
Investment case Strong trading & Scalable business Proven, adaptive $31Bn CNS R&D future revenue model operating in Innovation spend visibility from an attractive market Lower risk contracted order book investment in Pharma pipeline Management with a proven track record of delivering growth 6 BUSINE

Slide 7: Intelligent insights to improve clinical development
Intelligent insights to improve clinical development Consultancy: Early Phase: Late Phase: Post-Marketing: Optimising Defining and validating Deploying AI and site Providing biomarker biomarker selection biomarkers for management at scale for assessment to safety and efficacy standardised regulatory

Slide 8: Clinical development: investment in CNS is increasing
Unmet clinical need: investment in CNS is increasing Dementia pipeline 663 Discovery -1.7% 33% Rare CNS disease 992 940 Other therapeutic areas 1855 Pre-clinical 500 Phase 1 Clinical development 39.5% 438 5.6% 1,110 340 22.4% 21.5% 436 Phase 2 96.4% -11.1% 224 220 6.7% 165 138 111 174 Phase 3 Pain D

Slide 9: Biopharma is investing in neuro; emerging biotechs fuelling early pipeline growth
Biopharma is investing in neuro; emerging biotechs are fuelling early pipeline growth Early Phase Late Phase AbbVie, Biogen, Boehringer Ingelheim, Lilly, Novartis, Roche, Sanofi, Takeda, Roche, Lilly, AbbVie, Dementia UCB, AC Immune, Alkahest, Araclon, Biogen, Novartis, Axon, Denali, Oryzon, Sunovio

Slide 10: Long term client relationships provide revenue visibility
Long term client relationships provide revenue visibility New rare New client PSP & disease Psychiatric Contracts. imaging Plus HD extension $0.9M £1.0m PSP Scope expansion Two new rare $2.4M diseases Sept 2018 contracts £19.3M £1m Order Book New HD study 2 AD study AD Scope £2.3M Sept 2019 expansio

Slide 11: Financial Results
Financial Results Grant Nash, CFO

Slide 12: Financial performance
Financial performance 40% 660bps £1.1m 7.6 65 59 0.5 56 5.4 45 4.1 3.1 -0.6 -1.4 -2.1 2016 2017 2018 2019 2016 2017 2018 2019 2016 2017 2018 2019 ̶ FY19 +40% ̶ Growing margins ̶ Accelerated profitability ̶ FY18 +32% ̶ Operating leverage ̶ 6% EBITDA margin ̶ FY17 +34% ̶ Increasing data analytics ̶ Ah

Slide 13: Strategic KPI's
Strategic KPI’s 4.6 Productivity £3.4m Top 20 Pharma 124 140 Mid Pharma 120 19.3 Biotech 94 15.9 100 2.2 75 80 12.7 1.8 1.7 1.9 9.9 1.5 1.6 51 60 1.3 1.3 1.2 40 0.5 0.5 20 60 54 57 61 0 2016 2017 2018 2019 2016 2017 2018 2019 2016 2017 2018 2019 Avg FTEs Rev per FTE (£’000) ̶ 2018 benefited from PII

Slide 14: Investing for future growth; controlling costs
Investing for future growth; controlling costs £0.2m £0.4m £0.3m 2.0 60% 1.4 70% 64% 3.5 52% 1.2 3.0 1.2 60% 56% 2.7 3.0 50% 1.5 31% 1.0 50% 2.3 2.5 40% 0.8 0.8 0.8 2.0 40% 0.8 40% 51% 2.0 1.0 0.2 30% 19% 25% 20% 0.6 30% 1.5 15% 20% 14% 15% 0.5 0.4 20% 1.0 10% 0.2 10% 0.5 1.6 1.3 1.0 1.0 - 0% - 0% -

Slide 15: Strengthening Balance Sheet
Strengthening Balance Sheet £0.5m £0.6m £0.1m 611 7.9 7.2 7.3 7.3 3.1 2.4 3.3 2.5 112 75 52 -0.1 -0.1 24 55 49 49 -1.2 -2.0 2016 2017 2018 2019 2016 2017 2018 2019 2016 2017 2018 2019 Capex (£,000) Depr. (£’000) Cash (£m) Op Cashflow (£m) ̶ Growing working capital ̶ Infrastructure ̶ Stable operating

Slide 16: 3 Year Track Record
3 Year Track Record 12 10% 6% 0% 7.6 -10% 8 -12% -20% 5.4 4.1 -30% 4 3.1 -34% -40% 0.5 -50% 0 -60% -68% -0.6 -1.4 -70% -2.1 -4 -80% 2016 2017 2018 2019 Revenues (£M) EBITDA (£M) EBITDA Margin % 16 BUSINESS USE ONLY © IXICO plc 2019

Slide 17: Scaling our AI Technology Platform
Scaling our AI Technology Platform Giulio Cerroni, CEO 17 BUSINESS USE ONLY © IXICO plc 2019

Slide 18: Artificial Intelligence is not new
Artificial Intelligence is not new Artificial Intelligence Any technique which Machine learning AI techniques that give computer Deep learning enables computers to mimic human behaviour the ability to learn without being A subset of ML which make explicitly programmed to do so the computation of mul

Slide 19: Unique capabilities combining to create a scalable technology services model
Unique capabilities combining to create a scalable technology services model Neuroscience State of the art Contextualised domain knowledge technology data Dementia Past and present trials Scientific partnerships Rare disease AI Natural history studies Psychiatry & Data Platform IXICO-sponsored studi

Slide 20: Future opportunities through investment in AI development & data acquisition
Future opportunities through investment in AI development & data acquisition Neuroscience State of the art Contextualised domain knowledge technology data Faster algorithm Greater accuracy Process automation Increasing data development cycles through improved to reduce costs; volumes and allow the i

Slide 21: Summary & Outlook
Summary & Outlook Giulio Cerroni, CEO

Slide 22: Ready to scale
Ready to scale Sixth consecutive Expanding Visibility to future Delivering Profitable reporting period franchise with revenues from operational & well capitalised; reporting +20% blue-chip large contracted gearing and continued delivery revenue growth. biopharma client order book & executing of sust

Slide 23: Appendix
Appendix

Slide 24: Over a decade of successful commercial application in Pharma
Over a decade of successful commercial application in Pharma Neuroscience State of the art Contextualised domain knowledge technology data Dementia ̶ LEAP technology initially developed for AD assessment and established with academic Key Opinion Leaders ̶ Well-established as automated analysis tool

Slide 25: Growth underpinned by 4 pillars of strength
Growth underpinned by 4 pillars of strength A growing portfolio Adaptive Established of innovative AI technology in an central model with A decade applications attractive market global reach of delivery Proven AI technology Diverse range of CNS Data analytics model Trusted partner with platform for

Slide 26: Strategic priorities
Strategic priorities Build scale International Market traction Innovation Collaborations expansional Deepen and broaden Further develop our Leveraging our the application of AI technology to biopharma client our technology by improve clinical access & data biopharma outcomes analytics technologies …

Slide 27: New Institutional Shareholders
New Institutional Shareholders Percentage Shareholder Date acquired No. of Shares allocation BGF Investment Management May-19 9,354,000 20% Octopus Investments May-18 6,708,400 14% Gresham House May-18 5,357,100 11% Canaccord Genuity Group May-19 5,118,149 11% Amati Global Investors May-18 5,031,300

Slide 28: 2019 Summary Income Statement
2019 Summary Income Statement: Revenue growth, margin accretion and profitable Income Statement 2019 2018 Variance Revenue growth ̶ Broadening range of neurological disease areas £’000 £’000 £’000 ̶ Across all phases of clinical development Revenues 7,561 5,394 2,167 ̶ With leading biopharmaceutical

Slide 29: 2019 Summary Balance Sheet
2019 Summary Balance Sheet: Investment in non-current assets and strengthened working capital position Income Statement 2019 2018 Variance Fixed & Intangible assets ̶ Investments in infrastructure, scale and £’000 £’000 £’000 innovation ̶ Capitalisation of R&D driving commercial growth Fixed & intan

Slide 30: 2019 Summary Cashflow
2019 Summary Cashflow: Capitalised to fund growth Cashflow 2019 2018 Variance Closing cash ̶ £7.3m cash held to support organic growth £’000 £’000 £’000 Operating cash flows ̶ £0.1m outflows 2019 aligned with outflows Cashflow from operating (130) (68) (62) from 2018 Cashflow from taxation - 423 (42
Source: Internet Archive copy of ixico.com
More decks from IXICO PLC
Investor Day (April 2026)20 slides · Apr 1, 2026
FY2025 Earnings Presentation20 slides · Dec 9, 2025
Investor Day (October 2025)53 slides · Oct 30, 2025
H1 2025 Earnings Presentation20 slides · May 2025
FY2024 Earnings Presentation24 slides · December 2024
FY2023 Earnings Presentation35 slides · Dec 5, 2023